重大事件即時報告 8-K 2026-06-29

Schrödinger因禮來收購Ajax獲5,700萬美元一次性付款

AI 繁中摘要

Schrödinger, Inc. (納斯達克代號：SDGR) 於2026年6月29日提交8-K申報，披露一項重大交易里程碑。因禮來公司（Eli Lilly and Company）完成收購Ajax Therapeutics, Inc.（「Ajax」），而Ajax為Schrödinger共同創辦的公司，Schrödinger已收取一筆約5,700萬美元（USD）的一次性現金付款。此外，Schrödinger仍有資格在Ajax達成特定臨床及監管里程碑時，獲得額外現金款項。

該8-K申報僅供監管披露用途（Regulation FD Disclosure），不作爲《交易所法》第18條下的「存檔」文件，亦不視爲按《證券法》或《交易所法》提交的任何申報中的引用文件，除非明確指明。

對投資者的潛在影響：此筆約5,700萬美元的即時現金流入，直接增加Schrödinger的流動資金及非經營收入，短期內可強化資產負債表。未來潛在的里程碑付款（金額及觸發條件未在本次申報中具體披露）可進一步提供上行收益，惟需視Ajax研發項目的進展而定。是次交易反映Schrödinger在藥物發現平台對外合作及資產變現方面的能力，或對股價構成正面催化。投資者應關注其後續季度業績報告中對該筆款項的會計處理及任何相關指引。

展開英文正文

sdgr-202606291540 Broadway24th FloorNew YorkNYFALSE000149097800014909782026-06-292026-06-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2026
________________________________________
Schrodinger, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________

Delaware001-3920695-4284541
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

(Commission File Number)

1540 Broadway, 24th Floor
New York, NY
10036
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (212) 295-5800
Not Applicable 
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading
Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareSDGRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01.    Regulation FD Disclosure.
In connection with the completion of Eli Lilly and Company’s acquisition of Ajax Therapeutics, Inc. (“Ajax”), a company co-founded by Schrödinger, Inc. (the “Company”), the Company received a cash payment of approximately $57 million. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones.
The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Schrödinger, Inc.

Date: June 29, 2026By:/s/ Yvonne Tran
Yvonne Tran
Chief Legal Officer and Corporate Secretary